MDM2 and diffuse large B-cell lymphoma: Our laboratory reported that APG-2575 exerts synthetic lethality with Bruton’s tyrosine kinase (BTK) and an MDM2-p53 inhibitor in the treatment of diffuse large B-cell lymphoma (DLBCL) [25].